Jiménez RMÁ, Cortés BCR, Murphy SC, Manzanilla GHA, Pacheco GC, Figueroa GR, Solares SME

Language: Spanish
References: 5
Page: 44-48
PDF size: 233.15 Kb.

ABSTRACT

Prostate cancer affects millions of men around the world, and it is considered as one of the most important neoplasia for its morbidity and mortality rates. Whereas its diagnosis is looked after by protocol at a ≥ 40 years age, most of the patients are ≥ 60 years old, and their quality of life is severely impaired by this malignancy. Prostate cancer treatment is quiet complex and comprehends the use of several drugs, chemo- and radiotherapy, and surgery. Most of the patients develop hormone dependent disease, and are treated with several anti-hormonal therapies, which go from pharmacological to surgical castration. This therapeutic approach impairs the bone metabolism at large, promoting malignancy hypercalcemia, pain, bone mineral density (BMD) loss, vertebral compression and pathologic fractures. So, the prostate cancer patient is affected by the disease itself and by its treatment. In the last years, potent bisphosphonates have shown their potential for preventing Cancer Treatment Induced Bone Loss (CTIBL). Bisphosphonates prevent the so called Skeletal Related Events (SREs), and are likely to exert a prophylactic action against metastatic disease, whereas the latter capability has to be proofed by more clinical trials. A group of mexican urologists, considered as opinion leaders in this issue, presents in this document a simple but updated guide for the management of bone disease among prostate cancer patients.

REFERENCES

1. Berruti A, Dogliotti L et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. J Urol. 2000; 164:1248-1253.

2. Petrylak DP. Docetaxel for the treatment of hormone refractory prostate cancer. Rev Urol. 2003;5(Suppl. 2): 514-21.

3. Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol. 2006; 176(6 Pt 2):572-5.

4. Hortobagyi G. Progress in the management of bone metastases: one continent at a time? J Clin Oncol. 2005; 23(15):2399-3301.

5. Mohar A, Frías-Mendívil M, et al. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Pública Mex. 1997;39(4): 253-258.